Journal
ARCHIVES OF OPHTHALMOLOGY
Volume 122, Issue 8, Pages 1171-1177Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/archopht.122.8.1171
Keywords
-
Categories
Funding
- NEI NIH HHS [EY02698, EY01867] Funding Source: Medline
Ask authors/readers for more resources
Objectives: To determine if low concentrations of H-7 (1-[5-isoquinoline sulfonyl]-2-methyl piperazine) topically applied to the eye increases outflow facility and decreases intraocular pressure (IOP) without affecting the cornea in monkeys, and to evaluate if the effect of H-7 on IOP is pressure dependent. Methods: Single or multiple doses of 5% H-7 or vehicle (20 muL) were administered topically to opposite eyes of normal monkeys. A single dose of 2% H-7 or vehicle (50 muL) was administered to the glaucomatous eye of monkeys with laser-induced unilateral glaucoma, with vehicle on day I and H-7 on day 2. Results: In normotensive eyes, 1 dose of 5% H-7 maximally decreased IOP by a mean +/- SEM of 2.5 +/- 1.0 mm Hg (-16.7% +/- 5.5%) at 3 hours. Higher baseline IOP and repeated dosing were associated with greater IOP reduction. Outflow facility was increased, but central corneal thickness was not affected. In glaucomatous eyes, 1 dose of 2% H-7 maximally decreased IOP by a mean +/- SEM of 5.8 +/- 0.6 mm Hg (-16.9% +/- 1.6%) at 2 hours. Conclusions: Five percent H-7 increases outflow facility and decreases IOP, but does not affect corneal thickness. Multiple doses of H-7 induce greater reduction of IOP than a single dose. The effect of H-7 on IOP may be pressure dependent. Clinical Relevance: Multiple topical treatments with low doses of H-7 or analogues may substantially reduce outflow resistance in the hypertensive eye without meaningfully affecting the cornea.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available